| Patent Number | Grant Date | Title | Applicant |
|---|---|---|---|
| EP3045466 | Oct 16, 2024 | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes | ASTRAZENECA AB |
| EP3076983 | Aug 14, 2024 | Ionic Aqueous Compositions | GEROLYMATOS INTERNATIONAL S.A. |
| EP3578169 | Jun 26, 2024 | Pharmaceutical Formulations Comprising 4-{(1 R)-2-[(6-{2-[(2,6-Dichlorobenzyl)Oxy]Ethoxy}Hexyl)Amino]-1-Hydroxyethyl}-2-(Hydroxymethyl)Phenol | GLAXO GROUP LIMITED |
| EP2464337 | Jun 26, 2024 | Pharmaceutical Composition And Administrations Thereof | VERTEX PHARMACEUTICALS INC. |
| EP1849470 | Mar 20, 2024 | Anticancer Drug Containing Alpha, Alpha, Alphatrifluorothymidine And Thymidine Phosphorylase Inhibitor | TAIHO PHARMACEUTICAL CO., LTD. |
| EP4028021 | Jan 24, 2024 | Use Of Nmn For The Prevention And/Or Treatment Of Pain, And Corresponding Compositions | NUVAMID SA |
| EP3209295 | Dec 6, 2023 | Methods Of Treating Ocular Conditions | OYSTER POINT PHARMA, INC. |
| EP3175853 | Nov 1, 2023 | Antineoplastic Combinations Of Neratinib And Capecitabine | WYETH LLC |
| EP3728313 | Oct 25, 2023 | Combination Anti Cancer Therapy With An Iap Antagonist And An Anti Pd-1 Molecule | DEBIOPHARM INTERNATIONAL SA |
| EP2914248 | Oct 18, 2023 | Pharmaceutical Compositions For The Treatment Of Cftr Mediated Diseases | VERTEX PHARMACEUTICALS INCORPORATED |
| Patent Number | Grant Date | Title | Applicant | Facing Oppositions |
|---|---|---|---|---|
| EP2478907 | Apr 14, 2021 | Methods And Compositions For Treating Cancer | COUGAR BIOTECHNOLOGY, INC. | 44 |
| EP2493466 | Mar 10, 2021 | Novel Antitumoral Use Of Cabazitaxel | SANOFI MATURE IP | 26 |
| EP2766040 | May 15, 2019 | Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab | F. HOFFMANN-LA ROCHE AG | 18 |
| EP3626270 | Oct 11, 2023 | New Use | NOVARTIS AG | 16 |
| EP3102187 | Mar 25, 2020 | Stable Pharmaceutical Compositions Containing Sitagliptin In The Form Of Immediate Release Tablets | GALENICUM HEALTH S.L. | 14 |
| EP2498759 | Aug 1, 2018 | Immediate Release Tablet Formulations | ASTRAZENECA AB | 12 |
| EP2981255 | Sep 14, 2022 | Therapeutic Uses Of Empagliflozin | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 10 |
| EP3038654 | Oct 30, 2019 | New Use | NOVARTIS AG | 9 |
| EP2400950 | May 22, 2019 | Pharmaceutical Formulations Comprising 4 {(1r) 2 [(6 {2 [(2,6 Dichlorobenzyl)Oxy] Ethoxy}Hexyl)Amino] 1 Hydroxyethyl} 2 (Hydroxymethyl)Phenol | GLAXO GROUP LIMITED | 8 |
| EP2350096 | Dec 11, 2019 | Methods Of Treating Hepatic Encephalopathy | SALIX PHARMACEUTICALS, LTD. | 8 |
Feel free to send us a message here and we will get back to you